Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration 21 CFR Parts 510, 520, 522, 524, 556, and 558
[Docket No. FDA-2014-N-0002]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Final rule; technical amendments.
 SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during November and December 2014. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a change of sponsorship of eight NADAs and nine ANADAs, and to make correcting amendments for a drug labeler code.
 DATES: This rule is effective March 13, 2015.
 FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, 
                        *george.haibel@fda.hhs.gov*.


SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during November and December 2014, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: 
                    *http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm*. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: 
                    *http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm*. In addition, Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE 68144, has transferred ownership of, and all rights and interest in, the following approved applications to Pharmgate LLC, 161 North Franklin Turnpike, Suite 2C, Ramsey, NJ 07446: File No.
Product name
21 CFR Cite065-480
Chlortetracycline Soluble Powder
520.441.138-934
PENNCHLOR SP (chlortetracycline, sulfamethazine, penicillin) Type A medicated articles
558.145.138-935
PENNCHLOR (chlortetracycline) Type A medicated articles
558.128.138-938
PENNOX (oxytetracycline) Type A medicated articles
558.450.138-939
NEO-OXY (neomycin sulfate and oxytetracycline) Type A medicated articles
558.455.140-680
TYLAN (tylosin phosphate) Type A medicated articles
558.625.140-681
TYLAN Sulfa-G (tylosin phosphate and sulfamethazine) Type A medicated articles
558.630.141-137
PENITRACIN (bacitracin methylenedisalicylate) 50 Type A medicated article
Not codified.200-026
PENNOX 343 (oxytetracycline)
520.1660d.200-154
PENNOX 200 (oxytetracycline)
558.450.200-295
PENNCHLOR 64 (chlortetracycline)
558.128.200-314
PENNCHLOR S (chlortetracycline)
558.140.200-354
PENNCHLOR (chlortetracycline)/COBAN (monensin)
558.355.200-356
PENNCHLOR (chlortetracycline)/DENAGARD (tiamulin)
558.600.( print page 13227)200-357
PENNCHLOR (chlortetracycline)/BIO-COX (salinomycin)
558.550.200-358
PENNCHLOR (chlortetracycline)/BMD (bacitracin MD)
558.76.200-359
PENNCHLOR (chlortetracycline)/DECCOX (decoquinate)
558.195.
 At this time, the regulations are being amended to reflect these changes of sponsorship. Following these changes of sponsorship, Pharmgate LLC will now be the sponsor of an approved application while Pennfield Oil Co. will no longer be the sponsor of an approved application. Also, Hikma Pharmaceuticals LLC, P.O. Box 182400, Bayader Wadi Seer, Amman, Jordan 11118, has informed FDA that it has changed its name to Hikma International Pharmaceuticals LLC. Accordingly, § 510.600 (21 CFR 510.600) is being amended to reflect these changes. In addition, FDA is amending § 510.600 and several sections of part 520 to reflect a correct drug labeler code for Akorn Animal Health, Inc. FDA is also amending the regulations in 21 CFR parts 520, 522, 556, and 558 to redesignate several sections to reflect alphabetical order and to make minor technical amendments. These corrections and technical amendments are being made to improve the accuracy of the animal drug regulations. Table 1—Original and Supplemental NADAs and ANADAs Approved During November and December 2014
NADA/ 
                             ANADA
Sponsor
New animal drug 
                             product name
Action
21 CFR 
                             Sections
FOIA 
                             Summary
NEPA 
                             Review200-575
Putney, Inc., One Monument Sq., suite 400, Portland, ME 04101
Carprofen Chewable Tablets
Original approval as a generic copy of NADA 141-111
520.309
yes
CE 1
                             2141-232
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007
SIMPLICEF (cefpodoxime proxetil) Chewable Tablets
Supplemental approval of chewable tablet dosage form for dogs
520.370
yes
CE 1
                             3200-512
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007
TRIAMULOX (tiamulin hydrogen fumarate) Liquid Concentrate
Original approval as a generic copy of NADA 140-916
520.2455
yes
CE 1
                             2200-573
Putney, Inc., One Monument Sq., suite 400, Portland, ME 04101
Dexmedetomidine HCl 
                             (dexmedetomidine hydrochloride)  
                             Injectable Solution
Original approval as a generic copy of NADA 141-267
522.558
yes
CE 1
                             2141-068
Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201
BAYTRIL 100 (enrofloxacin) 
                             Injectable Solution
Supplemental approval adding administration by intramuscular injection in swine and an indication for control of colibacillosis in groups or pens of weaned pigs
522.812
yes
CE1
                             4141-349
Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007
DRAXXIN 25 
                             (tulathromycin)  
                             Injectable Solution
Supplemental approval for treatment of bovine respiratory disease (BRD) in suckling calves, dairy calves, and veal calves
522.2630
yes
CE 1
                             4141-437
Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408
OSURNIA 
                             (florfenicol, terbinafine, betamethasone acetate) Otic Gel
Original approval for the treatment of otitis externa in dogs
524.955
yes
CE 1
                             3034-267
Intervet, Inc., 556 Morris Ave., Summit, NJ 07901
GENTOCIN DURAFILM 
                             (gentamicin sulfate and betamethasone)  
                             Ophthalmic Solution
Supplemental approval of additional safety information
524.1044i
yes
CE 1
                             3141-034
Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria
GAINPRO 
                             (bambermycins)  
                             Type A medicated article
Supplemental approval of a free-choice Type C medicated loose mineral feed without selenium for pasture cattle
558.95
yes
CE 1
                             2200-510 5
Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446
DERACIN 
                             (chlortetracycline)  
                             Type A medicated articles
Original approval as a generic copy of NADA 048-761
558.128
yes
CE 1
                             2141-258
Intervet, Inc., 556 Morris Ave., Summit, NJ 07901
ZILMAX (zilpaterol hydrochloride) Type A medicated article
Supplemental approval to provide for component feeding of Type C medicated feeds
558.665
yes
CE 1
                             2( print page 13228)141-276 5
Intervet, Inc., 556 Morris Ave., Summit, NJ 07901
ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus TYLAN (tylosin phosphate)  Type C medicated feeds
Supplemental approval to provide for component feeding of combination drug Type C medicated feeds
558.665
yes
CE 1
                             61
                         The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.2
                         CE granted under 21 CFR 25.33(a)(1).3
                         CE granted under 21 CFR 25.33(d)(1).4
                         CE granted under 21 CFR 25.33(d)(5).5
                         This application is affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,” December 2013.6
                         CE granted under 21 CFR 25.33(a)(2).
 This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. List of Subjects 21 CFR Part 510 Administrative practice and procedure
Animal drugs
Labeling
Reporting and recordkeeping requirements 21 CFR Parts 520, 522, and 524 Animal drugs 21 CFR Part 556 Animal drugs
Foods 21 CFR Part 558 Animal drugs
Animal feeds
 Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, 556, and 558 are amended as follows: PART 510—NEW ANIMAL DRUGS
 1.The authority citation for 21 CFR part 510 continues to read as follows: Authority:
                        21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e. 2.Amend § 510.600 as follows: a.In the table in paragraph (c)(1), in the entry for “Akorn Animal Health, Inc.”, in the ”Drug labeler code” column, remove “053599”, and in its place add “059399”; b.In the table in paragraph (c)(1), in the entry for “Hikma Pharmaceuticals LLC”, in the “Firm name and address” column, remove “Hikma Pharmaceuticals LLC”, and in its place add “Hikma International Pharmaceuticals LLC”; c.In the table in paragraph (c)(1), remove the entry for “Pennfield Oil Co.” and add an entry, in alphabetical order, for “Pharmgate LLC”; d.In the table in paragraph (c)(2), remove the entries for “000008”, “048164”, and “053599” and add entries, in numerical order, for “059399” and “069254”; and e.In the table in paragraph (c)(2), in the entry for “059115”, in the “Firm name and address” column, remove “Hikma Pharmaceuticals LLC”, and in its place add “Hikma International Pharmaceuticals LLC”. The additions and revisions read as follows: § 510.600
  
 (c) * * * (1) * * * Firm name and address
Drug labeler code*         *         *         *         *         *         *Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446
069254*         *         *         *         *         *         *
 (2) * * * Drug labeler code
Firm name and address*         *         *         *         *         *         *059399
Akorn Animal Health, Inc., 1925 West Field Ct., suite 300, Lake Forest, IL 60045*         *         *         *         *         *         *069254
Pharmgate LLC, 161 North Franklin Turnpike, suite 2C, Ramsey, NJ 07446( print page 13229)*         *         *         *         *         *         *
 PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
 3.The authority citation for 21 CFR part 520 continues to read as follows: Authority:
                        21 U.S.C. 360b. §§ 520.310 and 520.312
 4.Redesignate §§ 520.310 and 520.312 as §§ 520.301 and 520.302, respectively. § 520.309
 5.Redesignate § 520.309 as § 520.304 and revise newly redesignated § 520.304 by adding paragraph (b)(3) to read as follows: § 520.304
  
 (b) * * * (3) No. 026637 for use of product described in paragraph (a)(2) of this section as in paragraph (d) of this section.
 6.In § 520.370, revise paragraphs (a) and (b) and in paragraph (c)(2), remove “ *intermedius”*
                         and in its place add “
                        *pseudintermedius”*
                         to read as follows: § 520.370
  (a) 
                            *Specifications.*
                             (1) Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime. (2) Each chewable tablet contains cefpodoxime proxetil equivalent to 100 or 200 mg cefpodoxime. (b) 
                            *Sponsors.*
                             See sponsors in § 510.600(c) of this chapter for uses as follows: (1) No. 026637 for use of product in paragraph (a)(1) of this section as in paragraph (c) of this section. (2) No. 054771 for use of products in paragraph (a) of this section as in paragraph (c) of this section.
 § 520.441
 7.In § 520.441, in paragraph (b)(1), remove “048164” and in its place add “069254”. 8.Amend § 520.1660d as follows: a.In paragraph (b)(6), remove “048164” and in its place add “069254”. b.In paragraphs (d)(1)(ii)(A)( *3*), (d)(1)(ii)(B)(
                        *3*), and (d)(1)(ii)(C)(
                        *3*), revise the last sentence. The revisions read as follows: § 520.1660d
  
 (d) * * * (1) * * * (ii) * * * (A) * * * (
                            *3*) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254. (B) * * * (
                            *3*) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254. (C) * * * (
                            *3*) * * * Zero-day withdrawal for those products sponsored by Nos. 054771, 057561, 061133, and 069254.
 9.In § 520.2455, revise paragraphs (b)(3) and (c) to read as follows: § 520.2455
  
 (b) * * * (3) No. 054771 for the product described in paragraph (a)(3) of this section. (c) 
                            *Related tolerances.*
                             See § 556.732 of this chapter.
 PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
 10.The authority citation for 21 CFR part 522 continues to read as follows: Authority:
                        21 U.S.C. 360b. § 522.246
 11.In § 522.246, in paragraph (b)(3), remove “053599” and in its place add “059399”. 12.In § 522.558, revise paragraphs (a) and (b) to read as follows: § 522.558
  (a) 
                            *Specifications.*
                             Each milliliter of solution contains: (1) 0.1 milligrams (mg) dexmedetomidine hydrochloride; or (2) 0.5 mg dexmedetomidine hydrochloride. (b) 
                            *Sponsors.*
                             See sponsors in in § 510.600(c) of this chapter for use as in paragraph (c) of this section: (1) No. 026637 for use of product described in paragraph (a)(2) of this section; (2) No. 052483 for use of products described in paragraph (a) of this section.
 13.Amend § 522.812 as follows: a.Revise paragraph (b)(2); b.Remove paragraph (e)(3)(i); c.Redesignate paragraphs (e)(3)(ii) and (e)(3)(iii) as paragraphs (e)(3)(i) and (e)(3)(ii), respectively; and d.Revise newly redesignated paragraph (e)(3)(i). The revisions read as follows: § 522.812
  
 (b) * * * (2) No. 055529 for use of product described in paragraph (a)(1) of this section as in paragraph (e)(1) of this section, and use of product described in paragraph (a)(2) of this section as in paragraphs (e)(2)(i)(B), (e)(2)(ii)(B), (e)(2)(iii), (e)(3)(i)(B), and (e)(3)(ii) of this section. 
 (e) * * * (3) * * * (i) 
                            *Amounts and indications for use.*
                             (A) Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the treatment and control of swine respiratory disease (SRD) associated with 
                            *Actinobacillus pleuropneumoniae, Pasteurella multocida,**Haemophilus parasuis, Streptococcus suis,**Bordetella bronchiseptica,*
                             and 
                            *Mycoplasma hyopneumoniae.* (B) Administer, by subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the treatment and control of swine respiratory disease (SRD) associated with 
                            *Actinobacillus pleuropneumoniae, Pasteurella multocida,**Haemophilus parasuis,*
                             and 
                            *Streptococcus suis.* (C) Administer, either by intramuscular or subcutaneous (behind the ear) injection, a single dose of 7.5 mg/kg of body weight for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with 
                            *Escherichia coli*
                             has been diagnosed.
 14.In § 522.1222, revise paragraph (b) to read as follows: § 522.1222
  
 
 
 (b) 
                            *Sponsors.*
                             See Nos. 000859, 026637, 054628, 054771, 059399, and 063286 in § 510.600(c) of this chapter.
 § 522.2474
 15.In § 522.2474, in paragraph (b), remove “053599” and in its place add “059399”. 16.In § 522.2630, revise paragraphs (b)(1), (b)(2), (d)(1)(ii)(A), (d)(1)(ii)(B), and (d)(1)(iii) to read as follows: § 522.2630
  
 (b) * * * (1) Product described as in paragraph (a)(1) of this section for use as in paragraphs (d)(1)(i), (d)(1)(ii), (d)(1)(iii)(A), and (d)(2) of this section. (2) Product described as in paragraph (a)(2) of this section for use as in paragraphs (d)(1)(i), (d)(1)(ii)(B), (d)(1)(iii)(B), and (d)(2) of this section. 
 (d) * * * (1) * * * (ii) * * * (A) 
                            *Beef and non-lactating dairy cattle.*
                             For the treatment of bovine respiratory disease (BRD) associated with 
                            *Mannheimia haemolytica, Pasteurella multocida,**Histophilus somni,*
                             and 
                            *Mycoplasma bovis.*
                             For the control of respiratory disease in cattle at high risk of developing BRD associated with 
                            *M. haemolytica, P. multocida,**H. somni,*
                             and 
                            *M. bovis.*
                             For the treatment of infectious bovine keratoconjunctivitis (IBK) associated with 
                            *Moraxella bovis.*
                             For the treatment of bovine foot rot (interdigital necrobacillosis) associated with 
                            *Fusobacterium necrophorum*
                             and 
                            *Porphyromonas levii.* (B) 
                            *Suckling calves, dairy calves, and veal calves.*
                             For the treatment of bovine respiratory disease (BRD) associated with 
                            *Mannheimia haemolytica, Pasteurella multocida,**Histophilus somni,*
                             and 
                            *Mycoplasma bovis.* (iii) 
                            *Limitations.*
                             (A) Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. Do not use in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (B) Calves intended for human consumption must not be slaughtered within 22 days from the last treatment. Not for use in ruminating cattle. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 § 522.2662
 17.In § 522.2662, in paragraph (b)(4), remove “053599” and in its place add “059399”. § 522.2670
 18.In § 522.2670, in paragraph (b)(1), remove “053599” and in its place add “059399”. PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
 19.The authority citation for 21 CFR part 524 continues to read as follows: Authority:
                        21 U.S.C. 360b. 20.Add § 524.955 to read as follows: § 524.955
  (a) 
                            *Specifications.*
                             Each milliliter of gel contains 10 milligrams (mg) florfenicol, 10 mg terbinafine, and 1 mg betamethasone acetate. (b) 
                            *Sponsor.*
                             See No. 058198 in § 510.600(c) of this chapter. (c) 
                            *Conditions of use in dogs*
                            —(1) 
                            *Amount.*
                             Administer one dose (1 tube) per affected ear(s) and repeat administration in 7 days. (2) 
                            *Indications for use.*
                             For the treatment of otitis externa in dogs associated with susceptible strains of bacteria (
                            *Staphylococcus pseudintermedius*) and yeast (
                            *Malassezia pachydermatis*). (3) 
                            *Limitations.*
                             Federal law restricts this drug to use by or on the order of a licensed veterinarian.
 21.In § 524.1044i, revise paragraph (c)(2) to read as follows: § 524.1044i
  
 (c) * * * (2) 
                            *Indications for use.*
                             For treatment of external eye infections and inflammation.
 PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
 22.The authority citation for 21 CFR part 556 continues to read as follows: Authority:
                        21 U.S.C. 342, 360b, 371. § 556.738
 23.Redesignate § 556.738 as § 556.732. PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
 24.The authority citation for 21 CFR part 558 continues to read as follows: Authority:
                        21 U.S.C. 360b, 371. § 558.76
 25.In § 558.76, in paragraph (d)(1)(iv), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place add “069254”. 26.In § 558.95, add paragraph (d)(4)(v) to read as follows: § 558.95
  
 (d) * * * (4) * * * (v) Used as a free-choice Type C medicated loose mineral feed for pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers) as follows: (A) 
                            *Specifications.* Ingredient
International feed No.
PercentDeflorinated phosphate (20.5% calcium, 18.5% phosphorus)
6-01-080
42.50Sodium chloride (salt)
6-04-152
20.10Calcium carbonate (38% calcium)
6-01-069
15.45Corn distillers dried grains w/solubles
5-28-236
9.57Magnesium oxide
6-02-756
5.15Vitamin and trace mineral premix *

3.72Mineral oil

1.00Yeast (primary dehydrated yeast)
7-05-533
0.75Bambermycins Type A article (10 g/lb)

0.60Iron oxide
6-02-431
0.50Magnesium sulfate (67%)
6-02-758
0.32Copper sulfate
6-01-720
0.18( print page 13231)Potassium sulfate (0.33%)
6-06-098
0.16* Content of vitamin/trace mineral premix may be varied. However, they should be comparable to those used for other free-choice feeds. Formulation modifications require FDA approval prior to marketing. Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides Sec. 651.100 (CPG 7125.18).
 (B) 
                            *Amount per ton.*
                             120 grams. (C) 
                            *Indications for use.*
                             For increased rate of weight gain. (D) 
                            *Limitations.*
                             For free-choice feeding to pasture cattle (slaughter, stocker, and feeder cattle; and dairy and beef replacement heifers). Feed a non-medicated commercial mineral product for 6 weeks to stabilize consumption between 2.66 and 10.66 ounces per head per day. Feed continuously to provide 10 to 40 milligrams bambermycins per head per day. Daily bambermycins intakes in excess of 20 mg/head/day have not been shown to be more effective than 20 mg/head/day.
 27.Amend § 558.128 as follows: a.In paragraph (b)(1), remove “Nos. 054771, 048164, and 066104” and in its place add “Nos. 054771, 066104, and 069254”; b.In paragraphs (e)(4)(ii) and (iv), in the “Limitations” column, remove “048164” wherever it occurs and in its place add “069254”; c.In paragraphs (e)(1)(i), (ii), and (iii), (e)(2)(i), (ii), (iii), and (iv), (e)(3)(i), (ii), (iii), and (iv), (e)(4)(i), (ii), (iv), (vii), and (viii), and (e)(5)(i) and (ii), in the “Sponsor” column, remove “048164” wherever it occurs and in its place in numerical order add “069254”; and d.Revise paragraphs (e)(1)(iv), (e)(4)(v), and (e)(4)(ix). The revisions read as follows: § 558.128
  
 (e) * * * (1) * * * Chlortetracycline amount
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(iv) 500 g/ton
Chickens: For the reduction of mortality due to 
                                    *E. coli*
                                     infections susceptible to chlortetracycline
1. Feed for 5 d. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: zero withdrawal time
054771,
                                     069254.2. Feed for 5 d; withdraw 24 h prior to slaughter; do not feed to chickens producing eggs for human consumption
012286,
                                     054771, 
                                     066104, 
                                     069254.
 
 (4) * * * Chlortetracycline amount
Indications for use
Limitations
Sponsor*         *         *         *         *         *         *(v) 500 to 4,000 g/ton
Calves, beef and nonlactating dairy cattle; treatment of bacterial enteritis caused by 
                                    *E. coli*
                                     and bacterial pneumonia caused by 
                                    *P. multocida*
                                     susceptible to chlortetracycline
Feed continuously for not more than 5 days to provide 10 mg/lb body weight per day. To sponsor No. 054771 under NADA 046-699: 24-h withdrawal time 
                                     To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: Zero withdrawal time
054771
                                     069254*         *         *         *         *         *         *(ix) 350 mg/head/day
1. Beef cattle: For control of bacterial pneumonia associated with shipping fever complex caused by 
                                    *Pasteurella*
                                     spp. susceptible to chlortetracycline
Withdraw 48 h prior to slaughter. To sponsor No. 054771 under NADA 046-699: 48-h withdrawal time. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: Zero withdrawal time
012286,
                                     054771, 
                                     066104, 
                                     069254.2. Beef cattle (under 700 lb): For control of active infection of anaplasmosis caused by 
                                    *A. marginale*
                                     susceptible to chlortetracycline
Withdraw 48 h prior to slaughter. To sponsor No. 054771 under NADA 046-699: 48-h withdrawal time. To sponsor No. 054771 under NADA 048-761 and No. 069254 under ANADA 200-510: zero withdrawal time
012286,
                                     054771, 
                                     066104, 
                                     069254.
 § 558.140
 28.In § 558.140, in paragraph (b)(1), remove “048164” and in its place add “069254”. § 558.145
 29.In § 558.145, in paragraph (a)(2), remove “048164” and in its place add “069254”. § 558.195
 30.In § 558.195, in paragraph (e)(2)(iv), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place add “069254”. § 558.355
 31.In § 558.355, in paragraph (f)(1)(xiv)( *b*), remove “048164” and in its place add “069254”. § 558.450
 32.Amend § 558.450 as follows: a.In paragraph (a)(2), remove “048164” and in its place add “069254”; b.In paragraphs (d)(2)(iii), (d)(2)(iv), and (d)(4)(ii), in the “Limitations” column, remove “048164” wherever it occurs and in its place add “069254”; and c.In paragraphs (d)(1)(i), (ii), (iii), and (iv), (d)(2)(i), (ii), (iii), and (iv), (d)(3)(i) and (ii), (d)(4)(i), (ii), (iii), (iv), and (v), and (d)(5)(i), (ii), and (iii), in the “Sponsor” column, remove “048164” and in its place add “069254”. § 558.455
 33.Amend § 558.455 as follows: a.In paragraph (b), remove “Nos. 048164 and 066104” and in its place add “Nos. 066104 and 069254”; and b.In paragraphs (e)(1)(i), (ii), (iii), and (iv), (e)(2)(i), (ii), (iii), and (iv), (e)(3)(i) and (ii), and (e)(4)(i), (ii), (iii), (iv), (v), and (vi), in the “Sponsor” column, remove “048164” and in its place in numerical order add “069254”. § 558.550
 34.In § 558.550, in paragraphs (b)(3) and (d)(1)(xvi)( *c*), remove “048164” and in its place add “069254”. § 558.600
 35.Redesignate § 558.600 as § 558.612 and amend newly redesignated § 558.612 as follows: a.In paragraph (c), remove “§ 556.738” and in its place add “§ 556.732”; and b.In paragraph (e)(1)(iii), in the “Limitations” and “Sponsor” columns, remove “048164” and in its place in numerical order add “069254”. § 558.615
 36.Redesignate § 558.615 as § 558.600. § 558.625
 37.In § 558.625, in paragraph (b)(5), remove “048164” and in its place add “069254”. § 558.630
 38.In § 558.630, in paragraph (b)(2), remove “No. 054771” and in its place add “Nos. 054771 and 069254”. 39.Amend § 558.665 as follows: a.Revise paragraphs (d)(1) and (e)(1); b.Redesignate paragraph (d)(2) as paragraph (d)(4); and c.Add paragraphs (d)(2), (d)(3), (e)(7), and (e)(8). The revisions and additions read as follows: § 558.665
  
 (d) * * * (1) Labeling shall bear the following caution statements: “Zilpaterol hydrochloride is not for use in animals intended for breeding. Do not allow horses or other equines access to feed containing zilpaterol. Do not use in veal calves.” (2) Labeling of Type A medicated articles and Type B medicated feeds used to manufacture complete Type C medicated feeds shall bear the caution statements in paragraph (d)(3) of this section. (3) Labeling of complete Type C medicated feeds shall bear the following caution statements: “Not to be fed to cattle in excess of 90 mg zilpaterol/head/day in complete feed. If pen consumption of complete feed exceeds 26.5 lb/head/day (90 percent dry matter basis), zilpaterol should not be fed in complete feed.” 
 (e) * * * Zilpaterol in grams/ton
Combination grams/ton
Indications for use
Limitations
Sponsor(1) 6.8

Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed
Feed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg/head/day. Withdrawal period: 3 days
000061*         *         *         *         *         *         *(7) 6.8 to 24

Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed
Feed continuously to cattle during the last 20 to 40 days on feed to provide 60 mg zilpaterol hydrochloride per head per day. Withdrawal period: 3 days
000061(8) 6.8 to 24
Monensin 10 to 40, plus tylosin 8 to 10
Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to 
                                    *Eimeria bovis*
                                     and 
                                    *E. zuernii;*
                                     and for reduction of incidence of liver abscesses caused by 
                                    *Fusobacterium necrophorum*
                                     and 
                                    *Arcanobacterium*
                                     (
                                    *Actinomyces*) 
                                    *pyogenes*
Feed continuously to cattle during the last 20 to 40 days on feed to provide 60 mg zilpaterol hydrochloride per head per day. See paragraphs §§ 558.355(d) and 558.625(c). Monensin and tylosin as provided by No. 000986 in § 510.600(c) of this chapter. Withdrawal period: 3 days
000061
 Dated: March 9, 2015. Bernadette Dunham, Director, Center for Veterinary Medicine.


[FR Doc. 2015-05644 Filed 3-12-15; 8:45 am] BILLING CODE 4164-01-P